Yonglong Zhang

Yonglong Zhang

Auto-generated profile, based on publicly available information

Yonglong Zhang

Laboratory of Targeted Therapy and Precision Medicine, Department of Clinical Laboratory, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell Reports
Verified
Journal Article
Open access
LHLingli He
Lingli He
LYLiang Yuan
Liang Yuan
WYWentao Yu
Wentao Yu
YSYang Sun
Yang Sun
DJDan Jiang
Dan Jiang
LZLei Zhang
Lei Zhang
The Hippo signaling pathway maintains organ size and tissue homeostasis via orchestration of cell proliferation and apoptosis. How this pathway triggers cell apoptosis remains largely unexplored. Here, we identify NR4A1 as a target of the Hippo pathway that mediates the pro-apoptotic and anti-tumor effects of the Hippo pathway whereby YAP regulates the transcription, phosphorylation, and mitochondrial localization of NR4A1. NR4A1, in turn, functions as a feedback inhibitor of YAP to promote its degradation, thereby inhibiting the function of YAP during liver regeneration and tumorigenesis. Our studies elucidate a regulatory loop between NR4A1 and YAP to coordinate Hippo signaling activity during liver regeneration and tumorigenesis and highlight NR4A1 as a marker of Hippo signaling, as well as a therapeutic target for hepatocellular carcinoma.

10 October 2019 in Cell Cycle
Verified
Journal Article
Closed access
YZYonglong Zhang
Yonglong Zhang
YLYanfeng Liu
Yanfeng Liu
JDJinlin Duan
Jinlin Duan
HWHui Wang
Hui Wang
YZYuchen Zhang
Yuchen Zhang
JWJian Wang
Jian Wang
Gallbladder cancer (GBC) is the common malignancy of the bile tract system with extremely poor clinical outcomes, owing to its metastatic property and intrinsic resistance to the first-line drugs. Although it is well-established that cholesterol abnormity contributes to gallstone formation, a leading risk factor for GBC, the link of cholesterol homeostasis with GBC has not been investigated. The present study systematically examined the genes implicated in cholesterol homeostasis, and revealed altered gene expressions of de novo cholesterol biosynthesis and sterol sulfonation (SULT2B1), reduced bile acid synthesis (CYP7B1 and CYP39A1) and impaired sterol efflux (ABCA1, ABCG5, LCAT, and CETP) in GBC tissues. Suppression of cholesterol biosynthesis by lovastatin inhibited GBC cell proliferation possibly through attenuating the DNA repair process. Further investigation revealed lovastatin sensitized GBC cells to cisplatin-induced apoptosis and suppressed the activation of CHK1, CHK2, and H2AX during DNA damage response. By using chemically distinct statins, HMGCR depletion or supplementing mevalonate, the product of HMGCR, we showed the inhibitory effects on DNA repair process of lovastatin were due to the blockage of the mevalonate pathway. Subcutaneous xenograft mice model suggested lovastatin promoted the therapeutic efficacy of cisplatin, and significantly prolonged the survival times of tumor-bearing mice. Moreover, HMGCR ablation repressed tumor growth in vivo, which can be rescued partially by restored expression of HMGCR, suggesting the on-target effects of lovastatin. Therefore, our study provides the clinical relevance of cholesterol homeostasis with GBC progression, and highlights a novel intervention of combined use of lovastatin and cisplatin for GBC.

13 December 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
YZYonglong Zhang
Yonglong Zhang
YLYanfeng Liu
Yanfeng Liu
JDJinlin Duan
Jinlin Duan
HYHaibo Yan
Haibo Yan
JZJun Zhang
Jun Zhang
JLJie Liu
Jie Liu
Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related death. However, the underlying mechanism during hepatocarcinogenesis remains unclarified. Stable isotope labeling by amino acids in cell culture (SILAC) is a powerful quantitative strategy for proteome‐wide discovery of novel biomarkers in cancers. Hippocalcin‐like 1 (HPCAL1) is a calcium sensor protein. However, the biological function of HPCAL1 is poorly understood in cancers, including HCC. Herein, HPCAL1 was identified by SILAC as a novel hepatocarcinogenesis suppressor down‐regulated in HCC cell lines and tissues. Importantly, lost expression of HPCAL1 was associated with worse prognosis of HCC patients. Interestingly, secreted HPCAL1 protein in the plasma dropped dramatically in HCC patients compared with healthy donors. Receiver operating characteristic curve analysis showed that serum HPCAL1 at a concentration of 8.654 ng/mL could better predict HCC. Furthermore, ectopic expression of HPCAL1 suppresses cell proliferation, while depletion of HPCAL1 led to increased cell growth both in vitro and in vivo. Mechanistically, HPCAL1 directly interacted with p21Waf/Cip1 in the nucleus, which requires the EF‐hand 4 motif of HPCAL1 and the Cy1 domain of p21. This interaction stabilized p21Waf/Cip1 in an extracellular signal‐regulated kinase 1/2‐mitogen‐activated protein kinase‐dependent manner, which subsequently prevented p21Waf/Cip1 proteasomal degradation by disrupting SCFSkp2 and CRL4Cdt2 E3 ligase complexes, resulting in increased protein stability and inhibitory effect of p21Waf/Cip1. Notably, the tumor suppressive function of HPCAL1 was dependent on p21 in vitro and in vivo. Consistent with this observation, expression of HPCAL1 and p21Waf/Cip1 was positively correlated in HCC tissues. Conclusion: These findings highlight a novel tumor suppressor upstream of p21Waf/Cip1 in attenuating cell cycle progression and provide a promising diagnostic and prognostic factor, as well as a potential therapeutic target for HCC. (Hepatology 2016;63:880–897)

30 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DLDanyang Liu
Danyang Liu
YZYonglong Zhang
Yonglong Zhang
YWYingze Wei
Yingze Wei
GLGuoyuan Liu
Guoyuan Liu
YLYufeng Liu
Yufeng Liu
NZNong Zhang
Nong Zhang
Activation of AKT pathway by Nrf2/PDGFA feedback loop contributes to HCC progression

31 May 2024 in Cancer Letters
Verified
Journal Article
Closed access
YLYanfeng Liu
Yanfeng Liu
FWFan Wang
Fan Wang
GYGuoquan Yan
Guoquan Yan
YTYu Tong
Yu Tong
WGWenyun Guo
Wenyun Guo
QXQiang Xia
Qiang Xia

24 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYanan Wang
Yanan Wang
MLMengjun Luo
Mengjun Luo
FWFan Wang
Fan Wang
YTYu Tong
Yu Tong
LLLinfeng Li
Linfeng Li
YLYanfeng Liu
Yanfeng Liu
Tumour cell metabolic plasticity is essential for tumour progression and therapeutic responses, yet the underlying mechanisms remain poorly understood. Here, we identify Prospero-related homeobox 1 (PROX1) as a crucial factor for tumour metabolic plasticity. Notably, PROX1 is reduced by glucose starvation or AMP-activated protein kinase (AMPK) activation and is elevated in liver kinase B1 (LKB1)-deficient tumours. Furthermore, the Ser79 phosphorylation of PROX1 by AMPK enhances the recruitment of CUL4-DDB1 ubiquitin ligase to promote PROX1 degradation. Downregulation of PROX1 activates branched-chain amino acids (BCAA) degradation through mediating epigenetic modifications and inhibits mammalian target-of-rapamycin (mTOR) signalling. Importantly, PROX1 deficiency or Ser79 phosphorylation in liver tumour shows therapeutic resistance to metformin. Clinically, the AMPK-PROX1 axis in human cancers is important for patient clinical outcomes. Collectively, our results demonstrate that deficiency of the LKB1-AMPK axis in cancers reactivates PROX1 to sustain intracellular BCAA pools, resulting in enhanced mTOR signalling, and facilitating tumourigenesis and aggressiveness.